The use of erythropoietin to treat anaemia in end-stage renal disease.
Recombinant human erythropoietin (r-HuEPO) has greatly improved the lives of renal patients with anaemia. Nurses who administer r-HuEPO should be aware of its side-effects. Studies are still needed to elicit the most efficient route of administration of r-HuEPO.